Abstract
The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others.
©2011 AACR.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Clinical Trials as Topic
-
Female
-
Humans
-
Molecular Targeted Therapy*
-
Receptor Cross-Talk
-
Receptor, ErbB-2 / metabolism*
-
Receptors, Estrogen / metabolism*
-
Signal Transduction / drug effects
-
Tamoxifen
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Hormonal
-
Receptors, Estrogen
-
Tamoxifen
-
ERBB2 protein, human
-
Receptor, ErbB-2